Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat:: Mapping of Emca1 and Emca2 to chromosomes 5 and 18

被引:45
作者
Gould, KA
Tochacek, M
Schaffer, BS
Reindl, TM
Murrin, CR
Lachel, CM
VanderWoude, EA
Pennington, KL
Flood, LA
Bynote, KK
Meza, JL
Newton, MA
Shull, JD
机构
[1] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA
[3] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
[4] Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Omaha, NE 68198 USA
[5] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[6] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA
关键词
D O I
10.1534/genetics.104.033878
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hormonal genetic and environmental factors plan major roles in the complex etiology of breast cancer. When treated continuously with 17beta-estradiol (E2) the ACI rat exhibits a genetically conferred propensity to develop mammary cancer. The susceptibility of the ACI rat to E2-induced mammary cancer appears to segregate as an incompletely dominant trait in crosses to the resistant Copenhagen (COP) strain. In both (ACI X COP)F-2 and (COP X ACI)F-2 populations, we find strong evidence fora major genetic determinant of susceptibility to E2-induced mammary cancer on distal rat chromosome 5. Our data are most consistent with a model in which the ACI allele of this locus, termed Emca1 (estrogen-induced mammary cancer 1). acts in an incompletely dominant manner to increase both tumor incidence and tumor multiplicity as well as to reduce tumor latency in these populations. We also find evidence suggestive of a Second locus. Emca2, on chromosome 18 in the (ACI X COP)F-2 population. The ACI allele of Emra2 acts in a dominant manner to increase incidence and decrease latency. Together, Emca1 and Emca2 act independently to modify susceptibility to E2-induced mammary cancer.
引用
收藏
页码:2113 / 2125
页数:13
相关论文
共 65 条
[1]  
An HX, 1999, CANCER RES, V59, P3941
[2]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[3]   Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women [J].
Bergman-Jungeström, M ;
Wingren, S .
BRITISH JOURNAL OF CANCER, 2001, 85 (06) :859-862
[4]   Epidemiology of endocrine-related risk factors for breast cancer [J].
Bernstein, L .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2002, 7 (01) :3-15
[5]   GENETIC ALTERATIONS IN BREAST-CANCER [J].
BIECHE, I ;
LIDEREAU, R .
GENES CHROMOSOMES & CANCER, 1995, 14 (04) :227-251
[6]   High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families [J].
Borg, Å ;
Sandberg, T ;
Nilsson, K ;
Johannsson, O ;
Klinker, M ;
Måsbäck, A ;
Westerdahl, J ;
Olsson, H ;
Ingvar, C .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1260-1266
[7]  
CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO
[8]  
2-Y
[9]  
CHURCHILL GA, 1994, GENETICS, V138, P963
[10]  
Clarke M, 1998, LANCET, V351, P1451